← FDA DRUG APPROVALS

FDA ANDA · ANDA211977

ESOMEPRAZOLE MAGNESIUM

Sponsor: HETERO LABS LTD III

APPLICATION
ANDA211977
TYPE
ANDA
ORIGINAL APPROVAL
2020-06-02
LATEST ACTION
2023-11-14
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Prescription

Products

ESOMEPRAZOLE MAGNESIUMPrescription
ESOMEPRAZOLE MAGNESIUM EQ 40MG BASE · CAPSULE, DELAYED REL PELLETS · ORAL
ESOMEPRAZOLE MAGNESIUMPrescription
ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2023-11-14Labeling · Supplement 9 · standardAP
2023-04-27Labeling · Supplement 8 · standardAP
2023-04-27Labeling · Supplement 1 · standardAP
2020-06-02UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →